Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069831
Filing Date
2025-05-13
Accepted
2025-05-13 08:30:21
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ck0001991792-20250331.htm   iXBRL 10-Q 1541075
2 EX-10.1 ck0001991792-ex10_1.htm EX-10.1 227634
3 EX-31.1 ck0001991792-ex31_1.htm EX-31.1 16641
4 EX-31.2 ck0001991792-ex31_2.htm EX-31.2 16429
5 EX-32.1 ck0001991792-ex32_1.htm EX-32.1 10740
6 EX-32.2 ck0001991792-ex32_2.htm EX-32.2 10815
  Complete submission text file 0000950170-25-069831.txt   6782734

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001991792-20250331.xsd EX-101.SCH 1074460
70 EXTRACTED XBRL INSTANCE DOCUMENT ck0001991792-20250331_htm.xml XML 945027
Mailing Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618
Business Address 400 SPECTRUM CENTER DRIVE SUITE 2040 IRVINE CA 92618 (949) 419-6203
CG Oncology, Inc. (Filer) CIK: 0001991792 (see all company filings)

EIN.: 371611499 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41925 | Film No.: 25937347
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)